Literature DB >> 19882917

[A case of slowly progressive intravascular lymphoma with respiratory failure caused by diffuse pulmonary vasoconstriction].

Akimasa Sekine1, Eri Hagiwara, Koji Okudera, Tomohisa Baba, Takashi Ogura.   

Abstract

A 71-year-old man developed intermittent fever with high serum lactate dehydrogenase in December 2006. Although persistent high grade fever and hypoxia appeared in July 2007, chest and abdominal CT showed no abnormal findings. On admission to our hospital in September 2007, chest CT demonstrated multiple micro-nodules in both lungs. Since diffuse lung capacity was extremely low and lung perfusion decreased diffusely, we performed video-associated lung biopsy and intravascular lymphoma was diagnosed. Histological examination of the lung specimen revealed a small number of atypical lymphocytes and some thrombi in capillaries. These findings suggested that severe hypoxia was caused mainly by diffuse pulmonary vasoconstriction due to some small thrombi and tumor cells, not by their embolization. Hypoxia improved dramatically in a few days after initiation of chemotherapy including rituximab.

Entities:  

Mesh:

Year:  2009        PMID: 19882917

Source DB:  PubMed          Journal:  Nihon Kokyuki Gakkai Zasshi        ISSN: 1343-3490


  2 in total

1.  Pulmonary Intravascular Large B-cell Lymphoma (IVLBCL) Disguised as an Asthma Exacerbation in a Patient with Asthma.

Authors:  Tomohito Takeshige; Norihiro Harada; Yasuhito Sekimoto; Ryota Kanemaru; Takeo Tsutsumi; Kei Matsuno; Satomi Shiota; Azuchi Masuda; Akihiko Gotoh; Miki Asahina; Toshimasa Uekusa; Kazuhisa Takahashi
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271

2.  Diffuse Cerebral Vasoconstriction in a Intravascular Lymphoma Patient with a High Serum MPO-ANCA Level.

Authors:  Atsuhiko Sugiyama; Makoto Kobayashi; Ayaka Daizo; Miyako Suzuki; Hirotoshi Kawashima; Shin-Ichiro Kagami; Hiroaki Tanaka; Yoshio Suzuki; Takashi Matsunaga; Satoshi Kuwabara
Journal:  Intern Med       Date:  2017-07-01       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.